ReelReactor™ is a cutting-edge continuous micro-batch reactor designed to revolutionize biologics manufacturing. Unlike traditional batch systems, which suffer from poor scalability, inconsistent quality, and high costs due to time-dependent reactions, ReelReactor enables precise, scalable, and cost-effective continuous production. Engineered for cell and gene therapy and other biologics, ReelReactor features functionally closed, sterile single-use consumables and biologically inert wetted materials. Its unique design ensures constant, gentle mixing, preserving product integrity, and it seamlessly integrates into larger workflows, eliminating bottlenecks. By bridging the gap between batch and continuous manufacturing, ReelReactor empowers biopharma companies to accelerate development, reduce manufacturing costs, and improve product consistency. Whether for feasibility studies, small-scale manufacturing, or full-scale production, ReelReactor provides an innovative, flexible platform to meet the evolving needs of modern bioprocessing.

Telos Biotechnology is revolutionizing cell therapy manufacturing with TELOVANCE™, a proprietary telomere-lengthening platform designed to enhance the expansion and efficacy of engineered cell therapies. Telos’ breakthrough technology addresses a critical limitation in CAR T-cell therapy—T-cell senescence and exhaustion, which contribute to poor long-term remission rates. The Challenge: CAR T-cell therapy has transformed cancer treatment, but nearly 50% of adult patients fail to achieve durable responses. One major contributor is immunosenescence, where T-cells progressively lose function due to telomere shortening, limiting their expansion potential and persistence. The Solution: TELOVANCE™ is a recombinant human telomerase holoenzyme that transiently extends telomeres during ex-vivo CAR T-cell manufacturing, increasing replicative lifespan and cytotoxicity without genetic modification. Our in-vitro and in-vivo data demonstrate that TELOVANCE-treated CAR T-cells outperform untreated counterparts in durability and anti-tumor activity. The telomerase enzyme is naturally degraded within 48 hours, ensuring safe and transient telomere elongation. Telos is actively collaborating with leading biotech, pharma and CDMO companies to integrate TELOVANCE™ into next-generation cell therapies. For partnership inquiries, visit TelosBio.com or email info@telosbio.com .